Market Overview

UPDATE: BMO Capital Markets Reiterates Market Perform Rating, Raises PT on Eli Lilly & Co.

Share:
Related LLY
The Drug Price Increase Debate: Separating The Winners From The Losers
7 Biggest Price Target Changes For Tuesday
Amgen Migraine Drug Likely To Beat Eli Lilly, Alder, Teva To Market (Investor's Business Daily)

In a report published Monday, BMO Capital Markets reiterated its Market Perform rating on Eli Lilly & Co. (NYSE: LLY), and raised its price target from $47.00 to $52.00.

BMO Capital Markets noted, “Eli Lilly provided financial guidance for 2013 and reconfirmed its mid-term guidance through 2014. The company reiterated its expectation to reach 2014 revenues of at least $20Bn and net income of at least $3Bn (consensus was $19.6Bn and $2.9Bn, respectively, on January 4, 2013). In 4Q12, Lilly repurchased roughly 16.9MM ($819MM) shares and plans to complete the remaining $1.1Bn of its share buyback program in 2013.”

Eli Lilly & Co. closed on Friday at $51.56.

Latest Ratings for LLY

DateFirmActionFromTo
Sep 2016Goldman SachsUpgradesNeutralBuy
Sep 2016JP MorganMaintainsOverweight
Sep 2016JP MorganUpgradesNeutralOverweight

View More Analyst Ratings for LLY
View the Latest Analyst Ratings

Posted-In: BMO Capital MarketsAnalyst Color Price Target Analyst Ratings

 

Related Articles (LLY)

View Comments and Join the Discussion!